128 related articles for article (PubMed ID: 35331992)
1. Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States.
Huepenbecker SP; Sun CC; Fu S; Zhao H; He W; Primm K; Giordano SH; Meyer LA
Int J Gynecol Cancer; 2022 Jul; 32(7):899-905. PubMed ID: 35331992
[TBL] [Abstract][Full Text] [Related]
2. Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States.
Huepenbecker SP; Sun CC; Fu S; Zhao H; Primm K; Giordano SH; Meyer LA
Cancer; 2021 Nov; 127(22):4151-4160. PubMed ID: 34347287
[TBL] [Abstract][Full Text] [Related]
3. Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States.
Huepenbecker SP; Sun CC; Fu S; Zhao H; Primm K; Rauh-Hain JA; Fleming ND; Giordano SH; Meyer LA
Int J Gynecol Cancer; 2022 Sep; 32(9):1153-1163. PubMed ID: 36166208
[TBL] [Abstract][Full Text] [Related]
4. Racial and socioeconomic disparities in adherence to preventive health services for ovarian cancer survivors.
Loomer L; Ward KC; Reynolds EA; von Esenwein SA; Lipscomb J
J Cancer Surviv; 2019 Aug; 13(4):512-522. PubMed ID: 31172430
[TBL] [Abstract][Full Text] [Related]
5. Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer.
Simmons D; Blank SV; ElNaggar AC; Chastek B; Bunner SH; McLaurin K
Adv Ther; 2022 Jun; 39(6):2544-2561. PubMed ID: 35362863
[TBL] [Abstract][Full Text] [Related]
6. Health Care Utilization Prior to Ovarian Cancer Diagnosis in Publicly Insured Individuals in New York State.
Gates Kuliszewski M; Boscoe FP; Wagner VL; Schymura MJ
J Registry Manag; 2021; 48(3):126-137. PubMed ID: 35413730
[TBL] [Abstract][Full Text] [Related]
7. Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data.
Huepenbecker SP; Zhao H; Sun CC; Fu S; He W; Giordano SH; Meyer LA
JCO Clin Cancer Inform; 2022 Mar; 6():e2100187. PubMed ID: 35297648
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer.
Fairfield KM; Murray K; LaChance JA; Wierman HR; Earle CC; Trimble EL; Warren JL
Gynecol Oncol; 2014 Sep; 134(3):473-7. PubMed ID: 24952367
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and Healthcare Burden of Patients with Schizophrenia Treated in a US Integrated Healthcare System.
Mahabaleshwarkar R; Lin D; Joshi K; Fishman J; Blair T; Hetherington T; Palmer P; Patel C; Krull C; Tcheremissine OV
J Ment Health Policy Econ; 2021 Jun; 24(2):47-59. PubMed ID: 34151777
[TBL] [Abstract][Full Text] [Related]
10. National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
Dottino JA; He W; Sun CC; Zhao H; Fu S; Rauh-Hain JA; Suidan RS; Lu KH; Giordano SH; Meyer LA
Int J Gynecol Cancer; 2020 Aug; 30(8):1195-1202. PubMed ID: 32616627
[TBL] [Abstract][Full Text] [Related]
11. Economic Burden of Inpatient Admission of Ankle Fractures.
Stull JD; Bhat SB; Kane JM; Raikin SM
Foot Ankle Int; 2017 Sep; 38(9):997-1004. PubMed ID: 28639869
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer: can we make the clinical diagnosis earlier?
Smith LH; Morris CR; Yasmeen S; Parikh-Patel A; Cress RD; Romano PS
Cancer; 2005 Oct; 104(7):1398-407. PubMed ID: 16116591
[TBL] [Abstract][Full Text] [Related]
13. Trends and racial disparities in aggressive end-of-life care for a national sample of women with ovarian cancer.
Mullins MA; Ruterbusch JJ; Clarke P; Uppal S; Wallner LP; Cote ML
Cancer; 2021 Jul; 127(13):2229-2237. PubMed ID: 33631053
[TBL] [Abstract][Full Text] [Related]
14. Healthcare utilization in women after abdominal surgery for ovarian cancer.
McCorkle R; Jeon S; Ercolano E; Schwartz P
Nurs Res; 2011; 60(1):47-57. PubMed ID: 21127451
[TBL] [Abstract][Full Text] [Related]
15. The end of life costs for Medicare patients with advanced ovarian cancer.
Urban RR; He H; Alfonso R; Hardesty MM; Goff BA
Gynecol Oncol; 2018 Feb; 148(2):336-341. PubMed ID: 29208368
[TBL] [Abstract][Full Text] [Related]
16. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
[TBL] [Abstract][Full Text] [Related]
17. Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study.
Machida H; Matsuo K; Yamagami W; Ebina Y; Kobayashi Y; Tabata T; Kanauchi M; Nagase S; Enomoto T; Mikami M
Gynecol Oncol; 2019 Jun; 153(3):589-596. PubMed ID: 30905436
[TBL] [Abstract][Full Text] [Related]
18. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer outcomes: Predictors of early death.
Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA
Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531
[TBL] [Abstract][Full Text] [Related]
20. Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
Charo LM; Jou J; Binder P; Hohmann SF; Saenz C; McHale M; Eskander RN; Plaxe S
Gynecol Oncol; 2020 Dec; 159(3):681-686. PubMed ID: 32977989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
